Core Insights - The company BeiGene is projected to achieve a revenue of $5.343 billion in 2025, representing a year-on-year growth of 40.2% [1] - The net profit is expected to reach $287 million, a significant turnaround from a net loss of $645 million in the same period last year [1] Financial Performance - Revenue forecast for 2025: $5.343 billion, up 40.2% year-on-year [1] - Expected net profit: $287 million, compared to a net loss of $645 million in the previous year [1]

Core Insights - The company BeiGene announced projected revenue of $5.343 billion for 2025, representing a year-over-year growth of 40.2% [1] - The company expects a net profit of $287 million, a significant turnaround from a net loss of $645 million in the same period last year [1] Financial Performance - Projected revenue for 2025 is $5.343 billion, indicating a robust growth trajectory [1] - The anticipated net profit of $287 million marks a substantial improvement compared to the previous year's net loss of $645 million [1]

Financial Performance - Total revenue for the year ended December 31, 2025, increased by approximately $1.5 billion or about 40.2% to approximately $5.3 billion compared to the year ended December 31, 2024[3]. - Product revenue for the year ended December 31, 2025, rose by approximately $1.5 billion or about 39.8% to approximately $5.3 billion compared to the previous year[3]. - Net profit for the year ended December 31, 2025, was approximately $286.9 million, a significant improvement from a net loss of approximately $644.8 million for the year ended December 31, 2024[3]. - Basic and diluted earnings per share for the year ended December 31, 2025, were $0.20 and $0.19, respectively, compared to losses of $0.47 per share for the previous year[3]. - The company reported a comprehensive income of approximately $357.7 million for the year ended December 31, 2025, compared to a comprehensive loss of approximately $694.3 million for the previous year[5]. - The company reported a net loss of $644,786,000 for the year ending December 31, 2024, which improved to a net profit of $286,933,000 for the year ending December 31, 2025[132]. Cash and Liquidity - Cash and cash equivalents as of December 31, 2025, were approximately $4.5 billion, up from approximately $2.6 billion as of December 31, 2024[6]. - Operating cash flow generated was $1,127,580 thousand, compared to an outflow of $140,631 thousand in the previous year[8]. - Cash and cash equivalents increased to $4,547,530 thousand by the end of 2025, up from $2,627,410 thousand at the end of 2024[9]. - The company raised $911,000 thousand from future royalty sales, contributing to a net cash inflow from financing activities of $1,059,451 thousand[9]. - Cash and cash equivalents increased significantly from $2,638.7 million in 2024 to $4,609.6 million in 2025, with operating cash flow generating $1.1 billion, a $1.3 billion increase year-over-year[180]. Assets and Liabilities - Total assets as of December 31, 2025, amounted to approximately $8.2 billion, compared to approximately $5.9 billion as of December 31, 2024[6]. - Total liabilities as of December 31, 2025, increased to approximately $3.8 billion from approximately $2.6 billion as of December 31, 2024[7]. - Shareholders' equity as of December 31, 2025, was approximately $4.4 billion, an increase from approximately $3.3 billion as of December 31, 2024[7]. - The company reported total liabilities of $3,827,379,000 as of December 31, 2025, compared to $3,332,222,000 in 2024, indicating an increase of about 14.9%[124]. - The total equity as of December 31, 2025, was $4,361,194,000, up from $3,332,222,000 in 2024, reflecting a growth of approximately 30.9%[124]. Research and Development - Research and development expenses increased to $510,857 thousand in 2025, up from $441,618 thousand in 2024[8]. - Research and development costs for 2025 amounted to $2,145,868,000, an increase from $1,953,295,000 in 2024[89]. - The company has over 20 CDAC and degradation antibody conjugate projects in drug discovery and clinical development stages, indicating a robust pipeline for future growth[143]. - Adjusted R&D expenses rose to $1.86 billion in 2025, up 11.3% from $1.67 billion in 2024[166]. Collaborations and Partnerships - The company has entered into collaboration agreements for the research, development, and commercialization of drugs, including royalty income from the sale of IMDELLTRA® outside China[23]. - The company received a $650 million upfront payment from Novartis for the collaboration and licensing agreement related to the development and commercialization of Tislelizumab in North America, Europe, and Japan[32]. - The company received a $300 million upfront payment from Novartis for the collaboration and licensing agreement concerning the TIGIT inhibitor Osemitamab, which was also terminated in July 2023[34]. - The company and Amgen signed multiple amendments to their collaboration agreement, expanding commercialization rights and adjusting financial responsibilities for specific products[28]. Tax and Regulatory Matters - The company confirmed Switzerland as its tax residency and adopted ASU 2023-09 starting from the fiscal year ending December 31, 2025, with a global effective tax rate of 31.2%[58]. - The deferred tax assets as of December 31, 2025, totaled $3,692,017,000, with a valuation allowance of $3,648,017,000, resulting in a net deferred tax asset of $44,000[62]. - The company incurred accrued interest and penalties of $2,676,000 in the U.S. and $3,264,000 in China related to uncertain tax positions as of December 31, 2025[64]. Employee and Stock Options - The company approved the 2018 Employee Stock Purchase Plan, reserving 3,500,000 shares initially, which was later increased to 12,425,315 shares by June 2024[95]. - The fair value of vested employee stock options rewards was $55,954,000 and $68,420,000 for the years ended December 31, 2025, and 2024, respectively[101]. - The estimated unrecognized compensation cost related to unvested stock options was $63,875,000, expected to be recognized over a weighted average period of 2.4 years[100]. Future Outlook and Strategy - The company plans to continue expanding its product offerings and market presence, particularly in the U.S. and China, with several new product launches anticipated[83]. - The company is focusing on lifecycle management to maximize value for shareholders and patients in the hematological oncology space, leveraging its cornerstone product Baiyueze®[144]. - The company is actively seeking strategic partnerships to strengthen its business and create long-term value for shareholders[146].

BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃百濟神州有限公司（BeOne Medicines Ltd., 「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條作出。 茲載列本公司於上海證券交易所網站刊發的《百濟神州有限公司關於續聘2026年 度審計機構的公告》，僅供參閱。 承董事會命 百濟神州有限公司 主席 歐雷強先生 香港，2026年3月25日 於本公告日期，本公司董事會包括主席兼執行董事歐雷強先生、非執行董事王 曉東博士，以及獨立非執行董事Olivier Brandicourt博士、Margaret Han Dugan 博士、Michael Goller先生、Anthony C. Hooper先生、Ranjeev Krishana先生、 Alessandro Riva博士、Corazon ( ...

A 股代码：688235 A 股简称：百济神州 公告编号：2026-004 港股代码：06160 港股简称：百济神州 美股代码：ONC 百济神州有限公司 关于续聘2026年度审计机构的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 拟聘任审计机构：安永华明会计师事务所（特殊普通合伙）为百济神州有 限公司（以下简称"公司"或"百济神州"）A 股财务报表和内部控制年度审 计机构；Ernst & Young（安永会计师事务所）为公司港股财务报表年度审计机 构；Ernst & Young LLP 为公司美股财务报表和内部控制年度审计机构；Ernst & Young AG 为公司瑞士法定审计机构。 一、续聘的审计机构的基本情况 （一）机构信息 1、安永华明会计师事务所（特殊普通合伙）（以下简称"安永华明"） （1）基本信息 安永华明于 1992 年 9 月成立，2012 年 8 月完成本土化转制，从一家中外合 作的有限责任制事务所转制为特殊普通合伙制事务所。安永华明总部设在北京， 注册地址为北京市东城区东长安街 ...

Group 1 - The core point of the news is the performance of the Science and Technology Innovation Pharmaceutical ETF (工银, 588860), which opened with a gain of 0.48% at 0.626 yuan on March 24 [1][2] - The ETF's major holdings showed positive movements, with notable increases including Zai Lab (泽璟制药) up 2.81%, BeiGene (百济神州) up 1.90%, and Honor Bio (荣昌生物) up 2.70% [1] - The ETF's performance benchmark is the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index, managed by ICBC Credit Suisse Asset Management Company, with a return of 24.70% since its inception on August 8, 2024, and a recent one-month return of -10.90% [2] Group 2 - The MACD golden cross signal has formed, indicating a positive trend for the stocks mentioned [3]

Investment Rating - The report suggests a positive investment outlook for the innovative drug sector, highlighting potential opportunities due to upcoming clinical data and successful overseas clinical progress of pipelines [2][4]. Core Insights - The chemical products sector is experiencing significant price increases due to rising international oil prices and high overseas energy costs, particularly affecting solvent products which are difficult to stockpile [1][10]. - The raw material pharmaceutical products are expected to see price increases as upstream raw material costs rise, with downstream clients maintaining low inventory levels since April 2023, indicating a potential for sustained price increases and profit elasticity [1][10]. - The report emphasizes the importance of the PI3K/AKT/mTOR signaling pathway in cancer treatment, with renewed focus on PI3K inhibitors, particularly following Novartis's acquisition of Synnovation Therapeutics' PI3Kα inhibitor SNV4818 [34][35][36]. Summary by Sections Raw Materials - The report notes that the pharmaceutical raw material sector is poised for price increases due to rising upstream costs and low inventory levels among clients, which could lead to sustained profitability [1][10]. Pharmaceuticals - Novartis announced a $2 billion upfront payment and up to $1 billion in milestone payments to acquire Synnovation Therapeutics' PI3Kα inhibitor SNV4818, indicating a strategic focus on differentiated therapies in the HR+/HER2- breast cancer market [2][34]. Medical Devices - Innovative products in the medical device sector are expanding into international markets, with companies like MicroPort receiving CE certification for pediatric applications of their surgical robots, enhancing their global brand presence [3][11]. Biologics - The report highlights the promising results of the oral GLP-1 Aleniglipron, which showed significant weight loss in clinical trials, suggesting a shift towards oral formulations that improve patient compliance and reduce logistics costs [3][12]. Traditional Chinese Medicine - The report suggests monitoring undervalued high-dividend assets within the traditional Chinese medicine sector as companies begin to release their performance results [3][12]. Healthcare Services and Consumer Healthcare - The report discusses the upcoming release of the DRG/DIP 3.0 version by the National Healthcare Security Administration, expected to be published around July 2023, which will provide insights into the evolving healthcare payment landscape [3][12]. Investment Recommendations - The report recommends focusing on core sectors such as small nucleic acids, bispecific antibodies, and ADCs, while also identifying opportunities during earnings forecast windows and major clinical data release events [2][4].

Summary of Key Points from the Conference Call Records Industry Overview - The protein degradation industry is entering a commercialization phase with technologies like PROTAC and molecular glue expected to gain regulatory approval in 2026, marking a shift from concept to product realization [1][2][20]. Core Insights and Arguments - **Technological Advancements**: AI-driven drug development is transitioning from serendipitous discovery to rational design, significantly enhancing the prediction accuracy of ternary complexes and accelerating the output of drug candidates [1][3][4]. - **Efficacy Improvements**: New generation degraders have surpassed a 95% efficiency threshold, with products like KT-621 demonstrating potential as "oral small nucleic acid" alternatives in autoimmune diseases [1][4]. - **Clinical Data**: BeiGene's BTK PROTAC achieved an overall response rate (ORR) of 94% in fourth-line treatment, outperforming similar products from Nurix, with safety risks to be monitored in upcoming data releases [1][12]. - **Market Trends**: The focus is shifting from tumor resistance targets to "undruggable" and autoimmune areas, with new platforms like LyTACs targeting extracellular and membrane proteins [1][7][8]. Milestones and Unique Advantages - **Upcoming Approvals**: Arvinas' ARV-471 and BMS' Abudomide are set for approval in mid-2026, representing significant milestones in the protein degradation field [2][20]. - **Mechanism of Action**: Protein degradation technologies offer advantages over traditional drugs by directly degrading target proteins, potentially overcoming resistance issues and expanding the range of druggable targets [2][3]. - **Patient Compliance**: Oral formulations of these drugs improve patient adherence compared to injectable therapies [2]. Key Players and Pipeline Progress - **Arvinas**: Leading in the PROTAC space with ARV-471 expected to be the first commercialized PROTAC drug, despite not showing a disruptive advantage over existing oral SERD drugs [9][20]. - **BMS**: Dominating the molecular glue sector with Abudomide and Iberdomide, both expected to show improved efficacy and safety profiles compared to older products [10][14]. - **Kymera Therapeutics**: Notable for its STAT6 PROTAC (KT-621), which has shown promising clinical data compared to Dupixent, with key data releases anticipated in 2027 [10][19]. - **BeiGene**: Fastest progress in the BTK PROTAC space, with significant clinical data expected by the end of 2026 [9][19]. Emerging Technologies and Future Directions - **LyTACs and DACs**: New platforms are in early stages, with LyTACs being the most mature for extracellular protein targeting, while DACs are still exploratory [6]. - **Monte Rosa Therapeutics**: Utilizing an AI platform for systematic drug discovery, with unique products targeting a wide range of autoimmune diseases [19][21]. - **C4 Therapeutics**: Developing IKZF1/3 molecular glue with promising safety profiles, aiming for rapid approval in the near future [17][18]. Investment Opportunities - **Key Companies to Watch**: - Revolution Medicines for its potential in pancreatic cancer treatment [21]. - Monte Rosa Therapeutics for its innovative AI platform [21]. - BeiGene for its leading position in the BTK PROTAC market [21]. - Kymera Therapeutics for its high ORR in clinical trials [21]. This summary encapsulates the critical developments and insights from the conference call records, highlighting the advancements and future potential within the protein degradation industry.

Core Viewpoint - The innovation drug sector in China is experiencing significant growth, driven by new drug approvals and favorable policy changes, with a focus on the performance of the ChiNext Innovation Drug ETF. Group 1: Market Performance - The ChiNext Innovation Drug Index rose by 3.42% as of March 17, 2026, with notable increases in constituent stocks such as Sangfor Biopharma (up 9.72%) and Yuandong Biotech (up 7.96%) [1] - The ChiNext Innovation Drug ETF (Huitianfu) increased by 3.23%, reaching a latest price of 0.8 yuan, and has seen a cumulative increase of 1.84% over the past week [1] - The ETF recorded a turnover rate of 3.90% with a trading volume of 19.21 million yuan, and an average daily trading volume of 33.78 million yuan over the past year [1] Group 2: Fund Growth and Inflows - The ChiNext Innovation Drug ETF saw a significant scale increase of 10.69 million yuan over the past two weeks, ranking in the top half among comparable funds [3] - The ETF's share count grew by 39 million shares in the past month, also placing it in the top half of comparable funds [3] - Despite a recent net outflow of 2.30 million yuan, the ETF experienced net inflows on 10 out of the last 15 trading days, totaling 30.51 million yuan [3] Group 3: Company Developments - Rongchang Biopharma's RC288 injection has received acceptance from the NMPA, showcasing promising anti-tumor activity and safety in preclinical studies [3] - Rongchang Biopharma is expected to enter a new growth phase starting in 2026, benefiting from new indications for RC18, RC48, and RC28, along with international sales starting in 2027 [4] - The company anticipates revenue from multiple asset authorizations beginning in 2025, which will enhance its financial statements [4] Group 4: Industry Trends - The new National Basic Medical Insurance Drug List has added 114 new drugs, including 50 innovative drugs, with a negotiation success rate of 88%, indicating a robust market for innovative drugs [5] - The commercialization of innovative drugs is accelerating, supported by improved payment systems and a green channel for insurance access [5] - The CXO industry is highlighted as a strong investment opportunity, with ongoing improvements in global pharmaceutical R&D and increasing collaboration between Chinese companies and multinational corporations [6]

Core Viewpoint - The company, BeiGene, stated that the recent changes in the value-added tax (VAT) policy will not significantly impact its profits, as it does not fall under the adjustment from a 3% simplified tax to a 13% general tax rate, and its VAT calculation method remains fundamentally unchanged [1] Group 1 - The company confirmed that it is not affected by the VAT policy change set to take effect on January 1, 2026 [1] - The company anticipates that the tax policy change will not have a major adverse effect on its profitability [1]